Analyst Patrick Trucchio from H.C. Wainwright reiterated a Buy rating on Beam Therapeutics and keeping the price target at $80.00.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Patrick Trucchio has given his Buy rating due to a combination of factors that highlight Beam Therapeutics’ advancements and potential in treating sickle cell disease (SCD) with their BEAM-101 therapy. The company is set to present significant clinical data at the upcoming American Society of Hematology Annual Meeting, showcasing the therapy’s durable efficacy and operational readiness. The data from the ongoing Phase 1/2 BEACON trial demonstrate BEAM-101’s consistent ability to correct hemoglobin levels, resolve anemia, and prevent vaso-occlusive crises in treated patients, which underscores its potential as a leading autologous cell therapy.
Additionally, Beam Therapeutics has made notable improvements in their manufacturing process, which enhances scalability and efficiency. The use of fixed-dose plerixafor mobilization has resulted in increased CD34+ yields with fewer collection cycles and reduced adverse events compared to traditional methods. These operational efficiencies position Beam Therapeutics as a competitive player in the field of gene editing, supporting the Buy rating due to the promising clinical outcomes and manufacturing advantages of BEAM-101.
According to TipRanks, Trucchio is a top 100 analyst with an average return of 34.8% and a 52.26% success rate. Trucchio covers the Healthcare sector, focusing on stocks such as Aligos Therapeutics, Precision BioSciences, and Altimmune.
In another report released today, Wells Fargo also maintained a Buy rating on the stock with a $70.00 price target.